Home Search
immunotherapy - search results
If you're not happy with the results, please do another search
USC Team IDs Biomarker for NSCLC Response to Chemoimmunotherapy
A team of researchers from USC Norris Comprehensive Cancer Center have identified a new biomarker that shows which patients with non-small cell lung cancer (NSCLC) will respond well to chemoimmunotherapy.
Startup Siren Biotechnology Touts Its AAV-Cytokine Immunotherapy as Potentially Effective against All Cancers
Siren Biotechnology, which combines AAV gene therapy and cytokine immunotherapy into a single transformative modality emerged from stealth mode this week as ASGCT.
Combination Oncolytic Virus and Immunotherapy Improved Overall Survival in Glioblastoma
The Phase I/II study, conducted by neurosurgeons at the University Health Network in Toronto, showed significant improvements in patient survival rates and tumor shrinkage.
Next-Generation Immunotherapy Stops Pancreatic Cancer Metastasis
Combining radiation with a novel immunotherapy drug was shown to stop metastasis in animal models of pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers.
Immunotherapy Substantially Improves Outcomes for Babies with Leukemia
Researchers led by a team from the Netherlands have shown that adding the immunotherapy blinatumomab to chemotherapy delays progression and improves survival for infants with an aggressive type of acute lymphoblastic leukemia.
Melanoma Immunotherapy Shows Promising Results in Mice
Researchers from King’s College London and Guy’s and St. Thomas’ NHS Foundation Trust report that their newly developed class of immunotherapy has shown promising results against melanoma.
Guardant and PICI Collaborate on Cancer Biomarker, Immunotherapy Response Study
Guardant Health and the Parker Institute for Cancer Immunotherapy (PICI) announced a collaboration on Tuesday to study the connection of cancer biomarkers and treatment response to immunotherapy spanning more than 14 different types of cancer.
Lung Cancer Outcomes Improve when Immunotherapy is Given Before and After Surgery
Pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC).
Personalized mRNA Vaccine Boosts Immunotherapy for High-Risk Melanoma
Researchers have developed a personalized mRNA-based vaccine, mRNA-4157, that significantly delays disease recurrence in patients with resected high-risk melanoma when added to standard-of-care adjuvant pembrolizumab therapy.
Immunotherapy Response in Advanced Melanoma Affected by Prior Treatments
Responses to the immunotherapy PD-1 checkpoint blockade in patients with advanced melanoma was tied to whether they had received a previous immunotherapy, CTLA-4 blockade, as well as other factors.
